US Federal Trade Commission staffers bring pharma focus
This article was originally published in Scrip
Executive Summary
The naming of a new US Federal Trade Commission ( FTC) chairman and senior staff suggest renewed antitrust scrutiny at the agency of the pharmaceutical and healthcare industries, including brand-generic patent settlements, under the Obama Administration.